Hologic (NASDAQ:HOLX) Updates Q1 Earnings Guidance

Hologic (NASDAQ:HOLX) updated its first quarter earnings guidance on Monday. The company provided EPS guidance of $1.00-1.03 for the period, compared to the consensus EPS estimate of $1.03. The company issued revenue guidance of $1.025-1.035 billion, compared to the consensus revenue estimate of $1.04 billion. Hologic also updated its FY 2025 guidance to 4.250-4.350 EPS.

Hologic Trading Down 1.4 %

Shares of NASDAQ HOLX traded down $1.09 during trading on Thursday, hitting $79.40. 500,300 shares of the company were exchanged, compared to its average volume of 1,590,213. The firm has a market capitalization of $18.44 billion, a PE ratio of 24.17, a P/E/G ratio of 3.03 and a beta of 0.98. Hologic has a 12-month low of $66.93 and a 12-month high of $84.67. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.32 and a current ratio of 3.99. The company has a fifty day moving average price of $81.05 and a 200-day moving average price of $78.12.

Hologic (NASDAQ:HOLX) last announced its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, hitting the consensus estimate of $1.01. Hologic had a net margin of 19.59% and a return on equity of 20.11%. The firm had revenue of $987.90 million for the quarter, compared to the consensus estimate of $978.25 million. During the same period in the prior year, the firm earned $0.89 EPS. The firm’s revenue for the quarter was up 4.5% on a year-over-year basis. As a group, equities research analysts expect that Hologic will post 4.36 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. Needham & Company LLC reiterated a “buy” rating and issued a $90.00 price objective on shares of Hologic in a research note on Tuesday, October 15th. JPMorgan Chase & Co. upped their price objective on Hologic from $92.00 to $94.00 and gave the stock an “overweight” rating in a report on Tuesday. Raymond James lifted their price target on shares of Hologic from $93.00 to $95.00 and gave the company an “outperform” rating in a research report on Tuesday. Leerink Partners cut their target price on shares of Hologic from $95.00 to $90.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. Finally, Evercore ISI increased their price objective on Hologic from $78.00 to $82.00 and gave the company an “in-line” rating in a research note on Tuesday, October 1st. Six equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $89.25.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.